AC Immune SA (ACIU)
ACIU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1651625/000110465926027342/0001104659-26-027342-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31. Converted from CHF at 0.8334 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | ACIU on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | 2016 |
| SEC CIK | 0001651625 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | V8 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.3M |
| Net income | -$84.5M |
| Operating income | Not in SEC XBRL data |
| Net margin | -1971.6% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 57.0× |
Reported in CHF; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2024-08-06 |
| Latest annual report | 20-F | 2026-03-13 |
| Latest quarterly / interim | 6-K | 2026-10-02 |
Source: SEC EDGAR submissions feed, 312 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMRN | Amarin Corporation plc | $11.58 | +0.43% | $244.6M |
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.31% | $243.0M |
| QTTB | Q32 Bio Inc. | $8.06 | -7.78% | $239.9M |
| VOGX | Vogenx Inc | $16.76 | -2.22% | $249.0M |
| BBOT | BridgeBio Oncology Therapeutics Inc. Common Stock | $2.95 | -9.51% | $236.5M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.30 | -7.26% | $252.5M |
| BCYC | Bicycle Therapeutics plc | $3.63 | -4.47% | $254.1M |
| BIOA | BioAge Labs Inc. | $5.57 | -6.23% | $255.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier